Last verified
Robotics focus and products
- Categories
- Surgical robotics, Medical robots
- Main products
- da Vinci surgical systems, Ion endoluminal system
- Industries
- Healthcare
- Company role
- Commercial
Questions for projects using Intuitive Surgical
Keep da Vinci and Ion indications, instruments and training requirements separate. Use the applicable device documentation and clinical evidence for the specific procedure. Do not infer independent surgical decision-making from robot-assisted instrument movement.
Editorial review . Product source dates remain listed above.
Company history and financial context
Origins and founders
- Founding year
- 1995
- Founder information
- Not yet confirmed for this profile
Intuitive’s financial reporting shows how a robotics business can combine equipment placements with recurring instruments, accessories and services. Placements include leased systems as well as equipment sales.
Technology and practical role
The da Vinci and Ion product families address different clinical workflows. Company revenue must not be treated as a measure of autonomous surgery or as sales in one country.
Financial information
Revenue US$10,064.7 million
Year ended 31 December 2025. Consolidated company revenue worldwide.
Reported earnings-release figure, unaudited
Includes instruments and accessories, systems and services. It is not equipment-only sales or a valuation.
Intuitive fourth-quarter 2025 earnings and operating modelNo valuation figure has been verified for this profile. This is a gap in this directory, not a statement that the company has never published the information.
What to check before a project
For a procurement review, separate system acquisition or lease costs from instruments, service, training and procedure-specific requirements. Assess clinical evidence separately from the business figures.
Sources for this section
Research additions reviewed . Historical figures retain their own reporting dates.